



⊌ f in

Events Jobs Subscribe

Volume 3.19: May 25

Intricate Genetic Programs Controlling Dormancy in *Mycobacterium* tuberculosis

First Author: Eliza Peterson (pictured) | Senior Author: Nitin Baliga Cell Reports | Institute for Systems Biology and UW



Publications of the Week

Mycobacterium tuberculosis (MTB) kills more people each year than any other infectious agent. Scientists developed an experimental platform to characterize MTB's response to changing O₂ levels in considerably more depth. They reveal detailed transcriptional dynamics and coordinated regulatory circuits that enable the pathogen's transition into and out of hypoxiainduced dormancy. Abstract

APOBEC3C Tandem Domain Proteins Create Super Restriction Factors against HIV-1

First Author: Mollie McDonnell | Senior Author: Michael Emerman (pictured) mBio | Fred Hutch and UW




APOBEC3C (A3C) is an example of a host antiviral protein, which weakly inhibits HIV-1. The authors show that the antiviral activity of A3C can be improved by duplicating the DNA sequence to create a synthetic tandem domain and, furthermore, that the proteins thus generated are relatively resistant to the viral antagonist Vif. Abstract

View All Publications 🔵

Awards

NIH Funds Kwon Lab Effort to Identify Genetic Risk Factors for Osteoporosis

Institute for Stem Cell & Regenerative Medicine, UW



With a major grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health, Drs. Claire Watson (pictured, left) and Ronald Kwon (pictured, right) from the UW Institute for Stem Cell and Regenerative Medicine faculty are on a mission to confront the root cause of osteoporosis. They are focusing on the primary determinant of bone health: our own genetics. Read More

Studying the Complex Interactions Between Antibodies and Viral Targets: Dr. Tal Einav Named Damon Runyon Quantitative Biology Fellow Fred Hutch



Dr. Tal Einav (pictured), a postdoctoral fellow in Dr. Jesse Bloom's lab, is among the first class of Damon Runyon Quantitative Biology Fellows. The prestigious award supports three years of cancer-related computational research jointly mentored by a computational biologist and cancer biologist. His work will focus on how the immune repertoire can be bolstered to better combat diseases. **Read More**

View All Awards 😜

Local News

Blood Test Monitors Long-Term Adherence to HIV Medications

Chemical & Engineering News



Researchers have developed a blood test that targets a long-lasting HIV drug metabolite present in blood cells. The test is a first step toward a low-cost, point-ofcare lab test that could reveal whether a person took their pills consistently over the previous several weeks. Senior author of the study, Dr. Jonathan Posner (pictured) at the University of Washington, says it has yet to be tested with real-world clinical samples. Read More

Antibody Neutralizes SARS and COVID-19 Coronaviruses UW Medicine

For several years, the laboratory of Dr. David Veesler (pictured) has been studying the structure and function of the infection mechanisms on a variety of coronaviruses. The S309 antibody, first identified in 2003, has been found to inhibit the cause of COVID-19. It is now on a fast-track development and testing path at Vir Biotechnology in the next step toward possible clinical trials. Read More

Fred Hutch Announces New Collaboration with Roche, Leveraging Digital **Technology to Help Cancer Patients Undergoing Chemotherapy** Fred Hutch



Cancer care and digital health experts at Fred Hutch have announced a collaboration with Roche, to develop and test a digital remote-monitoring system for cancer patients. Hutchinson Institute for Cancer Outcomes Research Director, Dr. Scott Ramsey (pictured) outlines their responsibility to look at technologies that could reduce the burden patients face. Read More

Skilled Partners in the Conduct of HIV Prevention Trials Join COVID-19 Response

HIV Vaccine Trials Network



The NIH-funded HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network have initiated their first clinical trial in response to COVID-19. Dr. Larry Corey (pictured), Principal Investigator, HVTN Leadership Operations Center, says this study will help create the infrastructure required to perform sophisticated SARS-CoV-2 vaccine trials. Read More

Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)

AGC Biologics



AGC Biologics, Seattle-based contract development and manufacturing organization for biopharmaceuticals, has announced its partnership with Takara Bio. The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine. Read More

View All Articles 👂 | Submit an Article 😜

Upcoming Events in Seattle

Diabetes and Metabolism Seminar Series May 27 10:00 AM

Exploring Career Paths: Taking Your Research to Market Impact May 28 3:00 PM

May 29 Immuno-Oncology: BD&L and Investment Forum 9:00 AM

UW Engage Science: Molecular Health, Medical Nanoparticles, June 1 **Counting Chromosomes** 6:00 PM

COVID-19 Research & Commercialization Funding June 4 10:00 AM

View All Events 🔵 | Submit an Event 😜

Science Jobs in Seattle

Research Associate I - Histology Allen Institute for Brain Science

Postdoctoral Research Associate Benaroya Research Institute at Virginia Mason

Postdoctoral Fellow - Piliponsky Lab Seattle Children's

Senior Associate Scientist - Life Cycle Management Bristol Myers Squibb

Director - Drug Safety & Risk Management

View 70 Other Science Jobs 👂 | Submit a Job 😜

STEMCELL **#StemCellfie Contest 2020**

Interviews and Updates on Stem Cell Science

BROUGHT TO YOU BY



The Stem Cell Podcast

STEMCELL's Science Newsletters

Free Weekly Updates on Your Field

STEMCELL Technologies Products | Services